What does INTERNATIONAL DRUG DEVELOPMENT INSTITUTE do?

INTERNATIONAL DRUG DEVELOPMENT INSTITUTE is a business association in Ottignies-Louvain-la-Neuve. Public Limited, started on 26 December 1988, 1 establishment.

What is the address of INTERNATIONAL DRUG DEVELOPMENT INSTITUTE?

The registered office of INTERNATIONAL DRUG DEVELOPMENT INSTITUTE is located at Avenue Provinciale 30, 1341 Ottignies-Louvain-la-Neuve.

Is INTERNATIONAL DRUG DEVELOPMENT INSTITUTE still active?

Yes. According to the CBE (16 September 2026) INTERNATIONAL DRUG DEVELOPMENT INSTITUTE is active, legal situation “Normale toestand”, started on 26 December 1988.

Is INTERNATIONAL DRUG DEVELOPMENT INSTITUTE registered on Peppol?

Yes, INTERNATIONAL DRUG DEVELOPMENT INSTITUTE is registered on the Peppol network with ID 0208:0436264032.

What is the enterprise number of INTERNATIONAL DRUG DEVELOPMENT INSTITUTE?

The enterprise number of INTERNATIONAL DRUG DEVELOPMENT INSTITUTE is BE0436264032.

When was INTERNATIONAL DRUG DEVELOPMENT INSTITUTE founded?

INTERNATIONAL DRUG DEVELOPMENT INSTITUTE was founded on 26 December 1988.

Who are the directors of INTERNATIONAL DRUG DEVELOPMENT INSTITUTE?

According to the 2025 annual accounts, the directors of INTERNATIONAL DRUG DEVELOPMENT INSTITUTE are: CLINIMETRICS SA, Amy FURLONG, Rob NICHOLS, Linda BENEZE, Bright Roads SA.

Is INTERNATIONAL DRUG DEVELOPMENT INSTITUTE a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 26 December 1988; 5 annual accounts filed, latest fiscal year 2025; 5 directors known from the annual account.

How much profit did INTERNATIONAL DRUG DEVELOPMENT INSTITUTE make in 2025?

INTERNATIONAL DRUG DEVELOPMENT INSTITUTE recorded a loss after taxes of € 1,129,247 in financial year 2025.

What is the revenue of INTERNATIONAL DRUG DEVELOPMENT INSTITUTE?

In its most recent annual accounts (2025), INTERNATIONAL DRUG DEVELOPMENT INSTITUTE reported revenue of € 11,894,916.

How much does an employee at INTERNATIONAL DRUG DEVELOPMENT INSTITUTE earn?

The average wage cost per full-time employee at INTERNATIONAL DRUG DEVELOPMENT INSTITUTE was € 106,500 in 2025: staff costs of € 8 million for 74.8 FTE, according to the annual account at the National Bank. That is the employer's cost, not net pay.

How many employees does INTERNATIONAL DRUG DEVELOPMENT INSTITUTE have?

According to the 2025 annual accounts, INTERNATIONAL DRUG DEVELOPMENT INSTITUTE has 74.8 full-time equivalents (FTE).

INTERNATIONAL DRUG DEVELOPMENT INSTITUTE (Public Limited)

Dossier INTERNATIONAL DRUG DEVELOPMENT INSTITUTE, printed on 16 September 2026 from databakkes.be/en/0436264032/international-drug-development-institute. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Shrinking team NBB

FTE fell two years in a row, from 98.9 to 74.8.
Figures corrected NBB

Corrected annual account filed for 2024.

Financials

Financial year 2025

INTERNATIONAL DRUG DEVELOPMENT INSTITUTE from Ottignies-Louvain-la-Neuve, company number BE0436264032, closed financial year 2025 with a result of € -1.1 million after tax. For that financial year INTERNATIONAL DRUG DEVELOPMENT INSTITUTE recorded revenue of € 11.9 million and equity of € 21 million. Compared with financial year 2024, the result moved from € 68.1 million to € -1.1 million. The company made a loss. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on June 16, 2026.

What it is worth Healthy

€ 21 million

▼ 6% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Loss Caution

€ -1.1 million

▼ still € 68.1 million profit in 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 1.3 million

▼ 41% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Caution

Loss, nothing to pay out

Reserves fell to € 20.6 million.

People and assets in 2025

Full-time equivalents

74.8

▼ 8.8 vs 2024

Average over the fiscal year, from the social balance sheet.

Wage cost Staff costs are payroll only. Director pay sits with services and miscellaneous goods: € 5.2 million in 2025, together with rent, insurance, accountants and other services. The accounts do not split that further.

€ 8 million

▼ 4% vs 2024

€ 106,500 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 368,762

▼ 3% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt ≈ 2 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 20,967

▼ 96% vs 2024

€ 11,678 is repaid this year. At this pace the long-term loan is gone in ≈ 2 years.

Owed to suppliers

€ 2 million

▲ 90% vs 2024

Supplier invoices still open on the last day of the fiscal year. Pays suppliers within 89 days on average.

Taxes and wages

€ 1.1 million

▲ 2% vs 2024

Taxes, VAT and social contributions still to pay.

Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Revenue	€ 14,801,095 Revenue 2022: € 14,801,095 First fiscal year in the series	€ 15,292,181 Revenue 2023: € 15,292,181 ▲ 3% vs 2022 (€ 14,801,095) Favourable step	€ 13,599,899 Revenue 2024: € 13,599,899 ▼ 11% vs 2023 (€ 15,292,181) Unfavourable step	€ 11,894,916 Revenue 2025: € 11,894,916 ▼ 13% vs 2024 (€ 13,599,899) Unfavourable step	▼ 13%
Profit after taxes	€ 720,031 Profit after taxes 2022: € 720,031 First fiscal year in the series	€ 90,742 Profit after taxes 2023: € 90,742 ▼ 87% vs 2022 (€ 720,031) Unfavourable step	€ 68,084,410 Profit after taxes 2024: € 68,084,410 ▲ € 68 million vs 2023 (€ 90,742) Favourable step	€ -1,129,247 Profit after taxes 2025: € -1,129,247 ▼ € 69.2 million vs 2024 (€ 68,084,410) Unfavourable step	▼ € 69.2 million
Equity	€ 3,414,158 Equity 2022: € 3,414,158 First fiscal year in the series	€ 3,254,900 Equity 2023: € 3,254,900 ▼ 5% vs 2022 (€ 3,414,158) Unfavourable step	€ 22,371,943 Equity 2024: € 22,371,943 ▲ € 19.1 million vs 2023 (€ 3,254,900) Favourable step	€ 20,992,696 Equity 2025: € 20,992,696 ▼ 6% vs 2024 (€ 22,371,943) Unfavourable step	▼ 6%
Total debts	€ 5,921,938 Total debts 2022: € 5,921,938 First fiscal year in the series	€ 5,959,071 Total debts 2023: € 5,959,071 ▲ 1% vs 2022 (€ 5,921,938) Unfavourable step	€ 53,180,319 Total debts 2024: € 53,180,319 ▲ € 47.2 million vs 2023 (€ 5,959,071) Unfavourable step	€ 6,579,186 Total debts 2025: € 6,579,186 ▼ 88% vs 2024 (€ 53,180,319) Favourable step	▼ 88%
Cash	€ 1,908,761 Cash 2022: € 1,908,761 First fiscal year in the series	€ 821,025 Cash 2023: € 821,025 ▼ 57% vs 2022 (€ 1,908,761) Unfavourable step	€ 2,267,684 Cash 2024: € 2,267,684 ▲ 176% vs 2023 (€ 821,025) Favourable step	€ 1,346,076 Cash 2025: € 1,346,076 ▼ 41% vs 2024 (€ 2,267,684) Unfavourable step	▼ 41%
Retained profit	€ 3,060,751 Retained profit 2022: € 3,060,751 First fiscal year in the series	€ 2,901,493 Retained profit 2023: € 2,901,493 ▼ 5% vs 2022 (€ 3,060,751) Unfavourable step	€ 22,018,536 Retained profit 2024: € 22,018,536 ▲ € 19.1 million vs 2023 (€ 2,901,493) Favourable step	€ 20,639,290 Retained profit 2025: € 20,639,290 ▼ 6% vs 2024 (€ 22,018,536) Unfavourable step	▼ 6%
Dividend	€ 850,000 Dividend 2022: € 850,000 First fiscal year in the series	€ 250,000 Dividend 2023: € 250,000 ▼ 71% vs 2022 (€ 850,000) Unchanged	€ 48,967,366 Dividend 2024: € 48,967,366 ▲ € 48.7 million vs 2023 (€ 250,000) Unchanged	€ 250,000 Dividend 2025: € 250,000 ▼ 99% vs 2024 (€ 48,967,366) Unchanged	▼ 99%
Bank debt	€ 5,801 Bank debt 2022: € 5,801 First fiscal year in the series	€ 42,808 Bank debt 2023: € 42,808 ▲ € 37,007 vs 2022 (€ 5,801) Unfavourable step	€ 526,105 Bank debt 2024: € 526,105 ▲ € 483,296 vs 2023 (€ 42,808) Unfavourable step	€ 20,967 Bank debt 2025: € 20,967 ▼ 96% vs 2024 (€ 526,105) Favourable step	▼ 96%
Balance sheet total	€ 9,374,368 Balance sheet total 2022: € 9,374,368 First fiscal year in the series	€ 9,237,705 Balance sheet total 2023: € 9,237,705 ▼ 1% vs 2022 (€ 9,374,368) Unchanged	€ 76,537,862 Balance sheet total 2024: € 76,537,862 ▲ € 67.3 million vs 2023 (€ 9,237,705) Unchanged	€ 28,471,882 Balance sheet total 2025: € 28,471,882 ▼ 63% vs 2024 (€ 76,537,862) Unchanged	▼ 63%
Employees (FTE)	95.1 Employees (FTE) 2022: 95.1 First fiscal year in the series	98.9 Employees (FTE) 2023: 98.9 ▲ 3.8 vs 2022 (95.1) Unchanged	83.6 Employees (FTE) 2024: 83.6 ▼ 15.3 vs 2023 (98.9) Unchanged	74.8 Employees (FTE) 2025: 74.8 ▼ 8.8 vs 2024 (83.6) Unchanged	▼ 8.8

Key figures of INTERNATIONAL DRUG DEVELOPMENT INSTITUTE, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to INTERNATIONAL DRUG DEVELOPMENT INSTITUTE?

What happened at INTERNATIONAL DRUG DEVELOPMENT INSTITUTE in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

2030 Bright Roads SA stepped down as director. NBB
Jun 16, 2026 New annual accounts for financial year 2025: loss of € 1.1 million (▼ € 69.2 million vs 2024). Source: NBB ↗
2025 CLINIMETRICS SA stepped down as director. NBB
2025 Amy FURLONG stepped down as director. NBB
2025 Rob NICHOLS stepped down as director. NBB
2025 Linda BENEZE stepped down as director. NBB
2023 Bright Roads SA became a director. NBB
2023 Amy FURLONG became a director. NBB

In short

From € 720,031 profit in 2022 to € 1.1 million loss in 2025.

Paid € 137,812 in corporate taxes since 2022.

Best year ever: 2024, with € 68.1 million profit.

Paid out € 50.3 million in dividends to the owners in total.

Original PDFs at the National Bank ↗

A new publication or filing at INTERNATIONAL DRUG DEVELOPMENT INSTITUTE? We notify you, reason included.

Follow INTERNATIONAL DRUG DEVELOPMENT INSTITUTE

Databakkes Pro

Know what changes at your customers, suppliers and competitors. Without reading an annual account.

Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.

Yes, I want that

See what a followed company gets: the De Lijn dossier

Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.

My folder 3 companies

De Lijn 8 June 2026 New annual account 2025

filed on 8 June 2026

What was left

€ 20 k ▼ 91%
Money in the bank

€ 178 k ▼ 98%

Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit

Real filings at the National Bank

Management

Bright Roads 97.2%

CLINIMETRICS

The stake of Bright Roads, CLINIMETRICS comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.

INTERNATIONAL DRUG DEVELOPMENT INSTITUTE

I.D.D.I. INC. 100%

The shares are held by Bright Roads (97.2%) and CLINIMETRICS. It owns 100% of I.D.D.I. INC. itself.

See the full network in the app

Directors

According to the 2025 annual accounts

CLINIMETRICS SA

Director · represented by Marc BUYSE

Also active at: Bright Roads, C3M3, One2Treat, CluePoints, NITYA

since 2016 · until 2025

Amy FURLONG

Chairman of the board

since 2023 · until 2025

Rob NICHOLS

Director

since 2023 · until 2025

Linda BENEZE

Director

Also active at: Bright Roads

since 2023 · until 2025

Bright Roads SA

Managing director · represented by Marc BUYSE

Also active at: One2Treat

since 2023 · until 2030

Shareholders

Bright Roads

97.2%

CLINIMETRICS

Participations

I.D.D.I. INC.

100%

Establishments

Establishment units

Physical locations of this company

Registered office

Avenue Provinciale 30

1341 Ottignies-Louvain-la-Neuve

2.041.499.513

Avenue Provinciale 430 box 14

1341 Ottignies-Louvain-la-Neuve

Active since 6 January 1989

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.

All companies at this address →

Bright Roads same network

€ 2.1 million revenue · 2025

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0436.264.032

VAT number

BE 0436.264.032

Registered office

Avenue Provinciale 30, 1341 Ottignies-Louvain-la-Neuve

Names & denominations

INTERNATIONAL DRUG DEVELOPMENT INSTITUTE · IDDI

Enterprise type

Rechtspersoon

Legal form

Public limited company

Legal situation

Normale toestand

Start date

26 December 1988

Peppol

Active · Active since 29 Dec 2025

Activities · NACE

Activiteiten van bedrijfs- en werkgeversorganisaties

Bedrijfs- en werkgeversorganisaties

Activiteiten van medische beeldvorming en medische laboratoria

Medische laboratoria

Activiteiten van medische laboratoria

View on CBE Public ↗ Annual accounts (NBB) ↗

INTERNATIONAL DRUG DEVELOPMENT INSTITUTE

Warning lights

Financials

What happened to INTERNATIONAL DRUG DEVELOPMENT INSTITUTE?

Know what changes at your customers, suppliers and competitors. Without reading an annual account.

Management

Directors

Shareholders

Participations

Establishments

Establishment units

Who else lives here?

Details

Frequently asked questions